Buer Li
YOU?
Author Swipe
View article: SLAMF7 promotes TCRαβ+ double negative T cell antitumor activity through enhancing glutamine metabolism
SLAMF7 promotes TCRαβ+ double negative T cell antitumor activity through enhancing glutamine metabolism Open
Background TCRαβ + double negative T cells (DNT) have recently gained attention for their antitumor activity. Adoptive DNT therapy has emerged as a promising cancer immunotherapy due to its potent cytotoxic function and lack of graft-versu…
View article: Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis
Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis Open
PBC-specific antibodies, along with elevated ALP and GGT levels, may occur in various non-PBC diseases. Etiological treatments may improve or even resolve cholestatic biochemistry. For these patients, initiating etiological treatment rathe…
View article: Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomena
Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomena Open
Background: Mildly elevated levels of transaminase and/or immunoglobulin G (IgG) are common in patients with primary biliary cholangitis (PBC). It is still unclear whether adding immunosuppressive therapy to ursodeoxycholic acid (UDCA) ben…
View article: Fenofibrate add-on therapy improves transplant-free survival in patients with primary biliary cholangitis refractory to ursodeoxycholic acid
Fenofibrate add-on therapy improves transplant-free survival in patients with primary biliary cholangitis refractory to ursodeoxycholic acid Open
Background Fenofibrate (FF) has shown biochemical benefit in primary biliary cholangitis (PBC) patients with a suboptimal response to ursodeoxycholic acid (UDCA), but the long-term efficacy on survival remains unknown. Methods In this retr…
View article: The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti‐mitochondrial antibodies but without baseline PBC
The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti‐mitochondrial antibodies but without baseline PBC Open
Anti‐mitochondrial autoantibodies (AMAs) are highly specific for the diagnosis of primary biliary cholangitis (PBC) but are also occasionally found in other diseases. In the present study, we evaluated the incidence of and predictors for P…
View article: Concomitant Gallstone Disease Was Associated With a Worse Prognosis in Non-Cirrhotic Patients With Primary Biliary Cholangitis
Concomitant Gallstone Disease Was Associated With a Worse Prognosis in Non-Cirrhotic Patients With Primary Biliary Cholangitis Open
Background & Aims: Primary biliary cholangitis (PBC) is a rare disease manifested as intrahepatic cholestasis, whereas gallstone disease is a common disease. Little is known on the prevalence and impact of gallstone disease (GD) on the cli…